1
|
Ramakrishna JM, Brumble LM, Larimore KL, Wadei HM, Jarmi T, Libertin CR. Establishing best practices in measles, mumps, and rubella serologic screening for kidney transplant candidates. Transpl Infect Dis 2020; 23:e13529. [PMID: 33248010 DOI: 10.1111/tid.13529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 09/21/2020] [Accepted: 11/01/2020] [Indexed: 11/28/2022]
Abstract
Optimizing immunity against vaccine-preventable diseases improves outcomes in kidney transplant (KT) patients (Arora et al, World J Transplant, 2019, 9:1; Sester et al, Transplant Rev, 2008, 22:274; Fishman, N Engl J Med, 2007, 357:2601). The American Society for Transplantation (AST) Clinical Practice Guidelines advises that serologic screening for measles, mumps, and rubella (MMR) be conducted for all KT candidates, since live-attenuated vaccines are contraindicated post-transplantation (Malinis et al, Clin Transplant, 2019, 33:e13548). Our team at Mayo Clinic Florida (MCF) conducted a quality improvement (QI) initiative to establish a best MMR screening and immunizations clinical practice in KT candidates using a Plan-Do-Study-Act (PDSA) model. By retrospective chart review of all KT candidates evaluated at our institution from January 1, 2016 to December 31, 2017, baseline data determining the rate of MMR serologic screening was established. PDSA cycles were implemented to adopt protocol-driven testing for MMR serologies, immunization documentation, and vaccination in cases of seronegativity to any of the three MMR viruses in all pre-KT candidates. Two PDSA cycles were completed in 4 months. The study population totaled 447 patients (baseline n = 283, PDSA 1 n = 61, PDSA 2 n = 103). Baseline data showed that 83% (n = 235) of pre-KT candidates received infectious disease consultation (IDC). Complete MMR (all three viruses) serological screening in KT candidates improved from baseline 3.9%-87.4% post-PDSA cycle 2 (P < .001). Necessary immunizations per AST guidelines were ordered in only 41.1% (n = 23) of the control cohort vs 100% (n = 12) and 96.9% (n = 31) of PDSA cycles 1 and 2, respectively (P < .001). The data reflect significant practice improvements in MMR screening and immunization rates among KT candidates by using protocol-driven orders combined with our pre-existing IDCs.
Collapse
Affiliation(s)
| | - Lisa M Brumble
- Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL, USA
| | - Kelly L Larimore
- Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL, USA
| | - Hani M Wadei
- Department of Transplant, Mayo Clinic, Jacksonville, FL, USA
| | - Tambi Jarmi
- Department of Transplant, Mayo Clinic, Jacksonville, FL, USA
| | | |
Collapse
|
2
|
Waldschmidt HV, Homan KT, Cruz-Rodríguez O, Cato MC, Waninger-Saroni J, Larimore KL, Cannavo A, Song J, Cheung JY, Koch WJ, Tesmer JJG, Larsen SD, Larsen SD. Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors. J Med Chem 2016; 59:3793-807. [PMID: 27050625 PMCID: PMC4890168 DOI: 10.1021/acs.jmedchem.5b02000] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
G protein-coupled receptors (GPCRs) are central to many physiological processes. Regulation of this superfamily of receptors is controlled by GPCR kinases (GRKs), some of which have been implicated in heart failure. GSK180736A, developed as a Rho-associated coiled-coil kinase 1 (ROCK1) inhibitor, was identified as an inhibitor of GRK2 and co-crystallized in the active site. Guided by its binding pose overlaid with the binding pose of a known potent GRK2 inhibitor, Takeda103A, a library of hybrid inhibitors was developed. This campaign produced several compounds possessing high potency and selectivity for GRK2 over other GRK subfamilies, PKA, and ROCK1. The most selective compound, 12n (CCG-224406), had an IC50 for GRK2 of 130 nM, >700-fold selectivity over other GRK subfamilies, and no detectable inhibition of ROCK1. Four of the new inhibitors were crystallized with GRK2 to give molecular insights into the binding and kinase selectivity of this class of inhibitors.
Collapse
Affiliation(s)
- Helen V. Waldschmidt
- Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109,Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, 48109,Departments of Medicinal Chemistry, Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, Michigan, 48109
| | - Kristoff T. Homan
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, 48109,Departments of Medicinal Chemistry, Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, Michigan, 48109
| | - Osvaldo Cruz-Rodríguez
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, 48109,PhD Program in Chemical Biology, University of Michigan, Ann Arbor, Michigan, 48109,Departments of Medicinal Chemistry, Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, Michigan, 48109
| | - Marilyn C. Cato
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, 48109,Departments of Medicinal Chemistry, Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, Michigan, 48109
| | - Jessica Waninger-Saroni
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, 48109,Departments of Medicinal Chemistry, Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, Michigan, 48109,Medical Scientist Training Program, University of Michigan, Ann Arbor, Michigan, 48109
| | - Kelly L. Larimore
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, 48109,Departments of Medicinal Chemistry, Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, Michigan, 48109
| | - Alessandro Cannavo
- Center for Translational Medicine, Temple University, Philadelphia, Pennsylvania, 19140
| | - Jianliang Song
- Center for Translational Medicine, Temple University, Philadelphia, Pennsylvania, 19140
| | - Joseph Y. Cheung
- Center for Translational Medicine, Temple University, Philadelphia, Pennsylvania, 19140
| | - Walter J. Koch
- Center for Translational Medicine, Temple University, Philadelphia, Pennsylvania, 19140
| | - John J. G. Tesmer
- Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, 48109,Departments of Medicinal Chemistry, Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, Michigan, 48109
| | - Scott D. Larsen
- Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109,Departments of Medicinal Chemistry, Pharmacology and Biological Chemistry, University of Michigan, Ann Arbor, Michigan, 48109,Corresponding Author: Scott D. Larsen, , (734) 615 - 0454
| | | |
Collapse
|